Investigation of TIMP2 Gene Polymorphisms Incidence in Patients with Breast Cancer

Ulviye Göksen Arslan 1, Recep Özmerdivenli 2, Kürşat Oğuz Yaykaşlı 3 * , Murat Oktay 4, Havva Erdem 4, Hatice Soğuktaş 1, Emine Yaykaşlı 1
More Detail
1 Düzce Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji ve Genetik Anabilim Dalı, Düzce
2 Düzce Üniversitesi, Tıp Fakültesi, Fizyoloji Anabilim Dalı, Düzce
3 Düzce Üniversitesi, Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, Düzce
4 Düzce Üniversitesi, Tıp Fakültesi, Tıbbi Patoloji Anabilim Dalı, Düzce
* Corresponding Author
EUR J BASIC MED SCI, Volume 2, Issue 4, pp. 101-105. https://doi.org/10.21601/ejbms/9188
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

The breast cancers were placed in first rank among other cancer types in women, and second rank after lung cancer in terms of death in the World. It is estimated that this cancer has 20/100.000 frequency in east region and 40-50/100.000 frequency west region according to present data in Turkey. Matrix Metalloproteinase (MMP), proteolytic enzymes involve in the breakdown of proteins located in the cell membrane and intercellular matrix such as collagen, elastin, proteoglycans, and gelatin. The tissue inhibitors of metalloproteinases (TIMPs) are proteins which are specific and natural inhibitor for MMPs. Its primary tasks regulate the activation of MMPs by suppress. The destruction of the balance between MMPs and TIMPs, may lead the emergence of pathological processes. In this study, the effect of TIMP2 (-418) G/C andTIMP2 (303) G/A polymorphisms in breast cancer patients in Turkish population were analyzed by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).The statistically significant difference was found between the control group and patients with breast cancer. However it is found that TIMP2 (303) GA genotype increases the risk of developing breast cancer at 1.486fold (p=0519), TIMP2 (-418) CC genotype increases the risk of developing breast cancer at 3.719-fold (p=0.519). In our knowledge, this study is the first to evaluate the relationship between breast cancer and TIMP2 gene polymorphisms in Turkish population. Our results show that there is no any association between breast cancer and TIMP2 gene polymorphisms in the community which is represented by our study and control groups. It was concluded from results that TIMP2 (303) GA genotype ile TIMP2 (-418) CC genotype may create the susceptibility to breast cancer.
Keywords: TIMP2, breast cancer, polymorphism

CITATION

Göksen Arslan U, Özmerdivenli R, Yaykaşlı KO, Oktay M, Erdem H, Soğuktaş H, et al. Investigation of TIMP2 Gene Polymorphisms Incidence in Patients with Breast Cancer. Eur J Basic Med Sci. 2012;2(4):101-5. https://doi.org/10.21601/ejbms/9188

REFERENCES

  • Ekmekçi A, Konaç E, Önen Hİ. Gen polimorfizmi ve kansere yatkınlık. Türkiye Marmara Medical Journal 2008; 21(3):282-95.
  • Koç Z, Sağlam Z. Kadınların meme kanseri, koruyucu önlemler ve kendi kendine meme muayenesi ile ilgili bilgi ve uygulamalarının belirlenmesi ve eğitimin etkinliği. Meme Sağlığı Dergisi 2009; 5(1):25-33.
  • Özmen V, Dünya’da ve Türkiye’de meme kanseri tarama ve kayıt programları. Meme Sağlığı Dergisi 2006; 2(1):55-8.
  • Ersin F, Bahar Z. Sağlığı geliştirme modelleri’nin meme kanseri erken tanı davranışlarına etkisi: Bir literatür derlemesi. Deuhyo ed 2012; 5(1):28-38.
  • Grubnik A, Benn C, Edwards G. Therapeutic Mammaplasty for Breast Cancer: Oncological and Aesthetic Outcomes. World J Surg 2013; 37(1):72-83.
  • Özmen V, Fidaner C, Aksaz E, Bayol Ü, Dede İ, Göker E, Güllüoğlu BM, Işıkdoğan A, Topal U, Uhri M, Utkan Z, Zengin N, Tuncer M. Türkiye’de meme kanseri erken tanı ve tarama programılarının Hazırlanması ‘Sağlık Bakanlığı meme kanseri erken tanı ve tarama alt kurulu raporu’. The Journal of Breast Health 2009; 5(3):125-34.
  • Gürocak ÖS, Sözen S, Üre İ, Erdem Ö, Akyol G, Alkibay T. Impact of tissue matrix metalloproteinase and its inhibitors on prognosis of patients with renal cell carcinoma. Türk üroloji dergisi 2008; 34(2):149-54.
  • Kaya Z. Meme kanserinde Matriks MetalloProteinaz1 ve 2 ekspresyonunun diğer prognostik faktörlerle ilişkisi, Uzmanlık Tezi, T.C. Sağlık Bakanlığı Okmeydanı Eğitim ve Araştırma Hastanesi Patoloji Bölümü. İstanbul 2008.
  • Efendioğlu M. Menengiomalı Hastalarda Matriks Metalloproteinaz 1 Geni Promotor Bölge Polimorfizminin Sıklığı ve İnvazyondaki Rolünün İncelenmesi, Uzmanlık Tezi, T.C. Sağlık Bakanlığı İstanbul Göztepe Eğitim ve Araştırma Hastanesi Nöroşirürji Servisi. İstanbul 2009.
  • Sağlam F. The role of matrix metalloproteinases in renal diseases. Turk Neph Dial Transpl 2011; 20(2): 109-14.
  • Güzel S. Akut miyokard infarktüsünde serum matriks metalloproteinaz-9 Düzeyleri. Uzmanlık Tezi. T.C. Sağlık Bakanlığı Taksim Eğitim ve Araştırma Hastanesi Biyokimya ve Klinik Biyokimya. İstanbul 2008.
  • Yamak N, Yaykasli KO, Soğuktaş H, Yaykaşlı E, Oktay M, Erdem H, Kaya E, Ekinci A, Kaya S, Kurman Y. Mide Kanseri Hastalarda Survivin Gen Polimorfizminin Araştırılması. Dicle Tıp Dergisi 2012; 39(4):499-503.
  • Park KS, Kim SJ, Kim KH, Kim JC. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepato 2011; 26(2):391-7.
  • Pulukuri SM, Patibandla S, Patel J, Estes N, Rao JS. Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 2007; 9;26(36):5229-37.
  • Rigg AS, Lemoine NR. Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther 2001; 8(11):869-78.
  • Langers AM, Verspaget HW, Hommes DW, Sier CF. Singlenucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. World J Gastrointest Oncol 2011; 3(6):79-98.
  • Singh RD, Haridas N, Patel JB, Shah FD, Shukla SN, Shah PM, Patel PS. Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem. 2010; 25(3):250-9.
  • Yan L, Lin B, Gao L, Gao S, Liu C, Wang C, Wang Y, Zhang S, Iwamori M. Lewis (y) Antigen Overexpression Increases the Expression of MMP-2 and MMP-9 and Invasion of Human Ovarian Cancer Cells. Int J Mol Sci 2010; 8;11(11):4441-52.
  • Srivastava P, Lone TA, Kapoor R, Mittal RD. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res 2012; 43(2):117-24.
  • Park KS, Kim SJ, Kim KH, Kim JC. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 2011; 26(2):391-7.
  • Wu CY, Wu MS, Chen YJ, Chen CJ, Chen HP, Shun CT, Chen GH, Huang SP, Lin JT. Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer 2007; 43(4):799-808.